Table 3.

Multivariate analysis of prognostic factors for survivals

Variable	BCFFS		CFFS		DMFS
	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
LVI
No	Ref		Ref		Ref
Yes	-	NS	9.73 (2.06–45.87)	0.004	5.96 (1.41–25.22)	0.015
pN-stage
No	Ref		Ref		Ref
Yes	8.74 (2.38–32.14)	0.001	-	NS	-	NS
PNI
No	Ref		Ref		Ref
Yes	11.86 (3.03–46.39)	<0.001	-	NS	-	NS
PSA at PORT (ng/mL)
≤0.2	Ref		Ref		Ref
0.2–0.5	-	NS	-	NS	-	NS
0.5–1.0	-	NS	-	NS	-	NS
>1.0	32.19 (5.82–177.85)	<0.001	19.62 (2.17–176.76)	0.008	10.46 (1.27–85.82)	0.029
NA-ADT
No	Ref		Ref		Ref
Yes	7.72 (2.81–21.25)	<0.001	11.10 (2.44–50.37)	0.002	-	NS
CA-ADT
No or unknown	Ref		Ref		Ref
Yes	0.05 (0.02–0.15)	<0.001	0.14 (0.02–0.70)	0.017	-	NS

BCFFS, biochemical failure-free survival; CFFS, clinical failure-free survival; DMFS, distant metastasis-free survival; HR, hazard ratio; CI, confidence interval; LVI, lymphovascular invasion; PNI, perineural invasion; PSA, prostate-specific antigen; PORT, postoperative radiotherapy; NA-ADT, neoadjuvant androgen deprivation therapy before PORT; CA-ADT, concurrent or adjuvant androgen deprivation therapy with PORT.